Obesity causes insulin resistance by increasing activation of the sympathetic nervous system and the release of the stress hormone norepinephrine, according to a new study.

Researchers at Baylor College of Medicine, Stanford University School of Medicine and collaborating institutions report in ...

Since semaglutide was approved by the FDA for weight loss under the brand name Wegovy in 2021, GLP-1 medications—originally ...

A recent study found semaglutide – the drug known as Ozempic – can improve knee pain in people with obesity and ...

GLP-1 receptor agonists, originally developed for managing type 2 diabetes, have rapidly emerged as highly effective ...

Since semaglutide was approved by the FDA for weight loss under the brand name Wegovy in 2021, GLP-1 medications—originally ...

Since semaglutide was approved by the FDA for weight loss under the brand name Wegovy in 2021, GLP-1 medications—originally ...

Since semaglutide was approved by the FDA for weight loss under the brand name Wegovy in 2021, GLP-1 medications—originally ...

The findings offer promising support for progressing ADPO-002NP treatment to first-in-human Phase I clinical trials. Adipo ...

The purine/purinergic system has emerged as a fundamental regulator of cellular communication, influencing various physiological processes such as metabolism, energy balance, and signal transduction.

The incidences of obesity and type 2 diabetes are increasing at alarming rates, and have become major health problems; treatments that involve lifestyle changes have had limited success.

A study published in the American Journal of Obstetrics and Gynecology demonstrates that when the diabetes drug metformin is ...